Trial Profile
A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms 16Y-LTF; 20Y-LTF; 21Y-LTF
- Sponsors Berlex Laboratories
- 30 Jun 2010 Added trial investigator, actual no. of pts and updated trial comment.
- 08 Jun 2010 Results from the 16-year follow-up to the pivotal Betaferon trial published in Neurology, according to a Bayer HealthCare media release.
- 29 Apr 2009 New data analyses presented at 61st Annual Meeting of the American Academy of Neurology.